BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Colon,
Lung,
Miscellaneous,
Pancreatic
Phase I
Adults
Chemotherapy - cytotoxic,
Mol. targeted/Immunotherapy/Biologics
5-FU (Fluorouracil),
BBO-11818,
Carboplatin,
Cetuximab,
Cetuximab (Erbitux),
Cisplatin,
Gemcitabine,
Leucovorin,
Liposomal Irinotecan,
Nab-Paclitaxel,
Oxaliplatin,
Pembrolizumab,
Pemetrexed
Eng, Cathy
National
Vanderbilt University
05-05-2026
Eligibility
18 Years and older
ALL
false
Inclusion Criteria:
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Exclusion Criteria:
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases
Known hypersensitivity to BBO-11818 or its excipients
Other inclusion/exclusion criteria are specified in the protocol.
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Exclusion Criteria:
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases
Known hypersensitivity to BBO-11818 or its excipients
Other inclusion/exclusion criteria are specified in the protocol.
